|Bid||0.00 x 1400|
|Ask||0.00 x 2200|
|Day's Range||26.29 - 26.60|
|52 Week Range||8.10 - 26.73|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Does Clementia Pharmaceuticals (CMTA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT ) Arena Pharmaceuticals, ...
The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy. THE GLOBE AND MAIL ** Canada's biotech startup Clementia ...
U.S. President Donald Trump's decision to delay an increase in tariffs on Chinese goods drove European shares to their highest since October with carmakers, most sensitive to the threat of a global trade war, leading the rally. The pan-European STOXX 600 closed up 0.3 percent and Germany's trade-sensitive DAX rose 0.4 percent. Italy's FTSE MIB outperformed the market, climbing 0.9 percent as government bonds jumped after Fitch affirmed the country's BBB credit rating.
French healthcare company Ipsen agreed to buy Clementia Pharmaceuticals Inc. Ipsen said it would pay $25 a share in cash initially for Clementia, plus a contingent value right of $6 a share upon Food and Drug Administration approval of Clementia's palovarotene drug for the treatment of multiple osteochondromas, a rare bone disorder. The companies said the initial cash consideration represents a premium of 77% to Clementia's 30-day volume-weighted average stock price.
Swiss pharma giant Roche Holdings AG Basel ADR (OTC: RHHBY) announced early Monday a deal to buy U.S.-based gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE) for $114.50 per share in cash, or a total equity value of $4.8 billion, including about $500 million of net cash expected at close. The per share value represents a 122.07-percent premium over Spark's Friday closing price of $51.56. Roche will commence a tender offer to acquire all outstanding shares of Spark, and upon completion will acquire the remaining untendered shares at the same price through a second step merger.
French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion (£1 billion), the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases. Ipsen's shares dipped 0.6 percent after the company said the takeover would initially weigh on margins due to the costs of forthcoming trials for Clementia products, but it hoped they would recover later on. Ipsen said it would buy all of Clementia's shares for $25 each in cash upfront and offer a contingent value right (CVR) purchase of $6.00 per share, giving a total transaction value of up to $1.31 billion.
French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases. Ipsen's shares dipped 0.6 percent after the company said the takeover would initially weigh on margins due to the costs of forthcoming trials for Clementia products, but it hoped they would recover later on. Ipsen said it would buy all of Clementia's shares for $25 each in cash upfront and offer a contingent value right (CVR) purchase of $6.00 per share, giving a total transaction value of up to $1.31 billion.
Ipsen said it would initially pay $25 a share in cash for Clementia, and a further $6 a share contingent on Clementia’s palovarotene drug receiving FDA approval for the treatment of a rare bone disorder. The deal will boost Ipsen’s participation in the treatment of rare diseases and bulk up its pipeline of future treatments, the company said. Ipsen will finance the transaction through existing cash and credit lines, which will significantly increase its net debt and have a dilutive effect on net income and operating margins.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]
A look at the shareholders of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...
Seeing as how we’re in the middle of earnings season, several stocks are in the spotlight due to earnings as well as other meaningful news. Among the stocks trending after hours include DryShips Inc. (NASDAQ:DRYS), Transocean Ltd (Switzerland) (NYSE:RIG), Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), EnerSys (NYSE:ENS), and Akamai Technologies Inc. (NASDAQ:AKAM). Let’s dive in more in depth. For those of you […]
Clementia Pharmaceuticals Inc.’s ( CMTA) shares were up 35.40% in pre-market trading after the Canada-based biotech firm announced plans to file a new drug application (NDA) supported by encouraging testing results. In a press release, Clementia said it is seeking approval of palovarotene to prevent heterotopic ossification (HO), the abnormal growth of bone in non-skeletal tissues, in patients that suffer from fibrodysplasia ossificans progressive (FOP), a rare and dangerous genetic bone disease. The biotech firm added that the Food and Drug Administration (FDA) agreed to let Clementia use Phase 2 data to support its application.
Biotechnology is a very interesting industry to invest in, but also very complex. If you are looking for stocks that are most likely to see their value surge, then your best bet would be to start with biotech companies. The industry focuses on development of novel therapies and drugs that can treat various conditions, therefore […]